



**MONOAMINE OXIDASE-A MODULATES APOPTOTIC CELL DEATH INDUCED
BY STAUROSPORINE IN HUMAN NEUROBLASTOMA CELLS**

Journal:	<i>Journal of Neurochemistry</i>
Manuscript ID:	JNC-E-2007-0379.R2
Manuscript Type:	Original Article
Date Submitted by the Author:	26-Jul-2007
Complete List of Authors:	Fitzgerald, Julia; Nottingham Trent University, School of Biomedical and Natural Sciences Ufer, Christoph; Nottingham Trent University, School of Biomedical and Natural Sciences De Girolamo, Luigi; Nottingham Trent University, School of Biomedical and Natural Sciences Kuhn, Hartmut; University Medicine Berlin-Charité,, Institute of Biochemistry Billett, E.; Nottingham Trent University, School of Biomedical and Natural Sciences
Keywords:	monoamine oxidase-A, apoptosis, SH-SY5Y, staurosporine, caspase, reactive oxygen species

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**MONOAMINE OXIDASE-A MODULATES APOPTOTIC CELL DEATH INDUCED BY
STAUROSPORINE IN HUMAN NEUROBLASTOMA CELLS**

Julia C. Fitzgerald,* Christoph Ufer, * Luigi A. De Girolamo, * Hartmut Kuhn,[†] and E.

Ellen Billett*

*** School of Biomedical and Natural Sciences, Nottingham Trent University, Clifton,
Nottingham, NG11 8NS, U. K.**

**[†] Institute of Biochemistry, University Medicine Berlin-Charité, Monbijoustr. 2, D-10117,
Berlin, F. R. Germany.**

**Address correspondence to: Professor Ellen, E. Billett, School of Biomedical and
Natural Sciences, Nottingham Trent University, Clifton lane, Clifton, Nottingham, NG11
8NS. U.K, Tel. (+44)115 8486356; Fax. (+44)115 8486355; E-Mail:
ellen.billett@ntu.ac.uk**

Abstract:

Monoamine oxidases (MAOs) are mitochondrial enzymes which control the levels of neurotransmitters in the brain and dietary amines in peripheral tissues via oxidative deamination. MAO has also been implicated in cell signalling. In this study we describe the MAO-A isoform as functional in apoptosis induced by staurosporine (STS) in human dopaminergic neuroblastoma cells (SH-SY5Y). Increased levels of MAO-A activity were induced by STS, accompanied by increased MAO-A protein and activation of the initiator of the intrinsic pathway, caspase-9, and the executioner caspase-3. MAO-A mRNA levels were unaffected by STS, suggesting that changes in MAO-A protein are due to post-transcriptional events. Two unrelated MAO-A inhibitors reduced caspase activation. STS treatment resulted in sustained activation of the MAPK pathway enzymes extracellular regulated kinase, c-jun terminal kinase and p38, and depletion of the anti-apoptotic protein Bcl-2. These changes were significantly reversed by MAO inhibition. Production of reactive oxygen species (ROS) was increased following STS exposure, which was blocked by both MAO inhibition and the antioxidant N-acetylcysteine. Therefore our data provide evidence that MAO-A, through its production of ROS as a by-product of its catalytic activity on the mitochondrial surface, is recruited by the cell to enhance apoptotic signalling.

Key words: Monoamine oxidase-A; apoptosis; SH-SY5Y; staurosporine; caspase; Reactive oxygen species.

Running title: Monoamine oxidase A in neuronal apoptosis

INTRODUCTION

Monoamine oxidase (MAO. EC 1.4.3.4) is a flavoenzyme tightly associated with the outer mitochondrial membrane. There are two forms (MAO-A and MAO-B) with 70% amino acid homology, coded for by two separate genes on the X chromosome (Bach *et al.* 1988). Monoamine oxidases metabolise amines to their corresponding aldehydes, with hydrogen peroxide (H₂O₂) and ammonia as by-products. MAO controls neurotransmitter levels and intracellular amine stores. The two isoforms have distinct substrate and inhibitor specificities, with MAO-A, for example, preferentially deaminating 5-hydroxytryptamine (serotonin, 5-HT) and inhibited by low concentrations of clorgyline (Fowler and Tipton, 1984). The MAO isoforms are differentially expressed in the CNS and peripheral tissues (reviewed by Billett, 2004). In human brain MAO-A is highly expressed in catecholaminergic neurons, including the dopaminergic neurons of the substantia nigra pars compacta (SNpc). In contrast, MAO-B is found in serotonergic neurons and astrocytes. It has been suggested that age-related increases in glial MAO-B expression may contribute to the aetiology of Parkinson's disease (PD) (Kumar *et al.* 2003) whilst MAO-A deficiency leads to aggressive behaviour in mice and humans (Shih *et al.* 1999).

Oxidative stress results from an imbalance of antioxidant defence mechanisms and generation of reactive oxygen species (ROS). ROS are important mediators in an array of biological processes, including cell growth (Yoon *et al.* 2002), cell signalling and apoptosis (Finkel, 1998). ROS have been implicated in various forms of cell death (Tatton and Olanow, 1999), and a range of pathological conditions including neurodegeneration (Schulz *et al.* 2000). Oxidative stress has particular relevance to PD, a disorder that causes damage to nigrostriatal dopaminergic neurons,

1
2
3 because dopamine itself can undergo autooxidation which can result in structural modification of
4 proteins (Stokes *et al.* 1999) and have deleterious effects on cellular respiration (Berman and
5 Hastings, 1999). Vulnerability of neurons to attack by free radicals is heightened by their low
6 glutathione content, which in PD is further reduced (Riederer *et al.* 1989).
7
8
9
10
11

12
13
14
15 A major source of ROS in the cell is the mitochondrial generation of superoxide anion due to
16 respiration (Abou-Sleiman *et al.* 2006). In addition, oxidative deamination of biogenic amines by
17 MAO is a key contributor to increased steady state concentrations of ROS (Cadenas and Davies,
18 2000). In dopaminergic neurons extravesicular dopamine is metabolised by MAO to produce
19 H₂O₂, which is further converted to hydroxyl radicals. Metabolism of amines by MAO causes
20 oxidative damage to mitochondrial DNA (Hauptmann *et al.* 1996) and directly damages the
21 electron transport system and affects antioxidant defence systems (Cohen and Kesler, 1999).
22 Additionally, subtle increases in H₂O₂ production caused by up-regulation of MAO-B in the rat
23 neuroblastoma cell line PC12 decreased mitochondrial complex I activity (Kumar *et al.* 2003).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 The role of MAO-A in dopaminergic cell death has been the focus of recent publications. It was
40 reported that induction of apoptosis by nerve growth factor deprivation in rat PC12 cells was
41 paralleled by an increase in MAO-A expression (DeZutter and Davis, 2001). This regulatory
42 process involved the p38 MAPK signal transduction pathway. On the contrary, MAO-A has been
43 found to be a target of a dopaminergic neurotoxin, N-methyl-R-salsolinol, and that in this case
44 inhibition of MAO led to apoptosis in the human neuroblastoma SH-SY5Y cell line (Yi *et al.*
45 2006). Most recently, Ou and co-workers (Ou *et al.* 2006) have reported that growth factor
46 deprivation via serum withdrawal led to a concomitant reduction in the transcription repressor
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 R1 (RAM2/CDCA7L/JPO2), increase in MAO-A expression (and activity) in SH-SY5Y cells,
4
5 and that inhibition of MAO activity prevented loss of cell viability.
6
7
8
9

10
11 In order to explore whether MAO-A is a key player in neuronal apoptosis we tested its impact in
12 another well established apoptotic model (staurosporine treated SH-SY5Y cells; Lopez and
13 Ferrer, 2000). Staurosporine is an unspecific protein kinase inhibitor which has frequently been
14 used as an inducer of the mitochondrial apoptotic pathway (Lopez and Ferrer, 2000). In this
15 study we monitored apoptosis via analysis of caspase activation and explored whether apoptosis
16 was linked to changes in MAO expression and activity, and how ROS and the MAPK pathways
17 were contributing to apoptotic cell signalling.
18
19
20
21
22
23
24
25
26
27
28

29 MATERIALS AND METHODS

30 Materials

31
32 SH-SY5Y neuroblastoma cells were obtained from the European Collection of Animal
33 Cell Cultures (Salisbury, UK). Staurosporine (STS), Acetyl-Asp-Glu-Val-Asp-7-
34 amidomethylcoumarin (caspase-3 fluorogenic substrate), ¹⁴C-labelled tyramine hydrochloride,
35 clorgyline, deprenyl, tranylcypramine, N-acetylcysteine (NAC), Dulbecco's Modified Eagles
36 Medium (DMEM) HAM's-F12 (1:1), Hank's Buffered Salt Solution, 3,3' diaminobenzidine,
37 anti-Bcl-2 monoclonal antibody, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
38 and ascorbic acid (vitamin C) were purchased from Sigma Aldrich (Dorset, U.K). 2', 7'-
39 Dichlorodihydrofluorecein diacetate (DCDHF) was obtained from Alexis Biochemicals
40 (Nottingham, UK). Anti-active caspase-8 and anti-active caspase-9 antibodies were purchased
41 from Upstate Biotechnology (Hampshire, UK). Anti-phosphorylated ERK, total ERK and anti-
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 phosphorylated JNK antibodies were purchased from Santa Cruz Biotechnology (Wiltshire, UK).
4
5 Anti-phosphorylated p38 and total JNK antibodies were from Cell Signalling Technology
6
7 (Hertfordshire, UK). Total p38 antibody was purchased from New England Biolabs (MA,
8
9 U.S.A). Anti-MAO-A (6G11-E1) and anti-MAO-B (3F12-G10-2E3) monoclonal antibodies
10
11 were made in our laboratory. Secondary antibodies were purchased from DakoCytomation
12
13 (Cambridgeshire, UK). Oligonucleotides were obtained from Biotex (Berlin, Germany).
14
15
16
17

18 19 20 **Cultures**

21
22 Human neuroblastoma SH-SY5Y cells were seeded at a density of approximately 4×10^4
23
24 cells/cm² on plastic culture plates, flasks (Starsted, Nümbrecht, Germany) or Lab-Tek® chamber
25
26 slides (NUNC, Roskilde, Denmark) and grown to 75-80 % confluence in DMEM HAM's-F12
27
28 medium containing 10 % (v/v) foetal bovine serum, 2 mM L-glutamine, 1 % (v/v) non-essential
29
30 amino acid solution, 100 units ml⁻¹ penicillin and 100 µg ml⁻¹ streptomycin at 37°C in a 5% CO₂
31
32 humidified atmosphere.
33
34
35
36
37
38
39

40 **Fluorogenic caspase-3 activation assay**

41
42
43 Caspase activity was monitored using a fluorogenic based assay with Acetyl-Asp-Glu-
44
45 Val-Asp-7-amidomethylcoumarin (Ac-DEVD-AMC) as substrate. Briefly, 500,000 cells were
46
47 seeded into 25cm³ flasks. On reaching 70-80% confluence the cells were pre-incubated for 2 h
48
49 with the required inhibitor then treated for 0-8 h with STS. After treatment both adherent and
50
51 floating cells were harvested by centrifugation at 300×g for 5 min. The pellet was washed twice
52
53 with DMEM, resuspended in 200-300 µl lysis buffer (50 mM HEPES, 5 mM CHAPS, 5 mM
54
55 DTT, pH 7.4) and incubated on ice for 20 min. The lysates were centrifuged at 200×g at 4°C for
56
57
58
59
60

1
2
3 5 min to remove cell debris. The assay was prepared in triplicate. Cell lysates were transferred to
4
5 black 96-well plates and made up to 80 μ l with assay buffer (20 mM HEPES pH 7.4, 0.1 % [w/v]
6
7 CHAPS, 5 mM dithiothreitol, 2 mM EDTA). Reactions were initiated by the addition of AC-
8
9 DEVD-AMC to a final concentration of 200 μ M in a total reaction volume of 100 μ l.
10
11 Fluorescence was measured (excitation 450 nm, emission 360 nm) every 20 min for 4 h at 37°C.
12
13 Data were normalised for protein content, which was determined by the Lowry method (Lowry
14
15 *et al.* 1951) and expressed as Δ fluorescence units/min/ μ g protein.
16
17
18
19

20 21 **MTT reduction assay**

22
23
24
25 SH-SY5Y cells were plated in 96-well plates at a density of ~ 20,000 cells/well and
26
27 grown to ~70-80 % confluence. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-
28
29 yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Briefly, following pre-treatment for
30
31 2 h with the required inhibitors, the cells were treated with 1 μ M STS in the presence and absence
32
33 of the MAO inhibitors. MTT stock solution in phosphate-buffered saline was added to each well
34
35 at a final concentration of 0.5 mg/ml and incubated for 30 min. The dark blue formazan crystals
36
37 formed in intact cells were solubilised in 100 μ l of dimethylsulfoxide and the absorbance
38
39 measured at 595 nm with a microtitre plate reader (Bio-Rad model 680, California, U.S.A).
40
41 Results are expressed as mean percent MTT reduction of the relevant control.
42
43
44
45
46

47 **MAO activity assay**

48
49
50 MAO activity was monitored using a radiometric assay with ¹⁴C-labelled tyramine
51
52 hydrochloride as substrate, based on the method of Russell and Mayer (Russell and Mayer, 1983)
53
54 with modifications. Treated cells were harvested as previously described and resuspended in 200
55
56 μ l potassium phosphate buffer (20 mM K₂HPO₄, 20 mM KH₂PO₄, pH 7.4) and 30 μ l aliquots
57
58
59
60

1
2
3 transferred to scintillation vials, in triplicate. Samples were made up to 200 μ l with potassium
4 phosphate buffer and then incubated at 37°C for 5 min. Sample blanks were prepared in parallel
5
6 containing, in addition, 200 μ l 0.5 M HCl. To each sample 20 μ l 1 mM 14 C-labelled tyramine
7
8 hydrochloride (1 mCi/mmol) was added and incubated for 1 h at 37°C. The reaction was stopped
9
10 by the addition of 200 μ l 0.5 M HCl. Finally, 3 ml scintillant (1:1 Ethyl acetate: toluene, 1 %
11
12 [w/v] PPO) was added to each vial, and a sample of the organic phase containing the product
13
14 transferred into a scintillation vial. MAO activity was measured in a liquid scintillation counter
15
16 (Cambera-Packard, Schwadorf, Germany). Preliminary assays were undertaken to ensure that
17
18 MAO activity was linear beyond the 1 h time point. Data were normalised for protein content,
19
20 which was determined by the Lowry method (Lowry *et al.* 1951) and rates expressed as
21
22 pmoles/min/mg protein.
23
24
25
26
27
28
29

30 **Gel Electrophoresis and Western blotting**

31
32
33
34 Cells exposed to STS in the presence and absence of inhibitors were extracted into
35
36 extraction buffer (50 mM Tris, 5 mM EDTA, 150 mM NaCl, 1 mM sodium orthovanadate, 2
37
38 mM PMSF, 1 % [w/v] SDS, and 0.2 % [v/v] protease inhibitor cocktail) and immediately boiled
39
40 for 5 min. Equal protein aliquots (100 μ g for analysis of MAPK proteins and 20 μ g for all others)
41
42 per sample were subjected to electrophoresis on a 12 % (v/v) SDS-polyacrylamide gel. Separated
43
44 proteins were transferred onto a nitrocellulose membrane and equal protein loading assessed by
45
46 staining with 0.05 % (w/v) copper phthalocyanine in 12 mM HCl, checked by immunodetection
47
48 of tERK, tJNK or tP38. Blotted membranes were blocked for 1 h in either 3 % (w/v) BSA (for
49
50 detection of phosphorylated proteins) or 3 % (w/v) dried skimmed milk (for other proteins) in
51
52 TBS containing 0.1 % (v/v) Tween-20 and incubated overnight at 4°C with primary antibodies.
53
54
55
56
57
58
59
60 Membranes were washed and incubated for 2 h at room temperature with peroxidase-conjugated

1
2
3 anti-mouse or anti-rabbit immunoglobulin G (dilution 1:1000). Antibody binding was revealed
4 with the ECL Western blotting detection reagent (Pierce, Rockford, Illinois, and U.S.A). Digital
5 images were captured using a LAS-3000 image-analyser (Fuji Film Co. Ltd., Tokyo, Japan), and
6 band intensity quantified using Aida software (Raytest GmbH, Straubenhardt, Germany).
7
8
9
10
11

12 **Dot blotting**

13
14
15
16
17 Treated cells were harvested, as previously described, and resuspended in 150 μ l MAO
18 extraction buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, 1 mM Na orthovanadate, 0.5 %
19 [w/v] Triton X-100, 2 mM PMSF and 0.2 % [v/v] protease inhibitor cocktail) and incubated on
20 ice for 20 min. Samples were centrifuged for 10 min at 300 \times g at 4°C. The supernatants were
21 sonicated (3 \times 3 second pulses at 60 Hz). Equal protein samples, in triplicate, were loaded onto a
22 Dot blot manifold and bound to a nitrocellulose membrane filter. Membranes were blocked for 1
23 h in 3 % (w/v) dried skimmed milk in TBS containing 0.1 % Tween-20 and incubated overnight
24 in monoclonal antibody anti-MAO-A 6G11-E1 (tissue culture supernatant) at 4°C. Membranes
25 were washed and incubated for 2 at room temperature with phosphatase-conjugated anti-mouse
26 immunoglobulin G (dilution 1:1000). Antibody binding was revealed in substrate buffer (0.75 M
27 Tris, pH 9.5) containing 0.13 mM nitroblue tetrazolium and 0.29 mM bromochloroindolyl
28 phosphate. Digital images were captured using a LAS-3000 image-analyser (Fuji Film Co. Ltd.,
29 Tokyo, Japan), and band intensity quantified using Aida software (Raytest GmbH,
30 Straubenhardt, Germany).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Detection of Reactive Oxygen Species (ROS)**

51
52 Cells were grown to ~70-80 % confluence on Lab-Tek (NUNC, Roskilde, Denmark)
53 chamber slides prior to pre-treatment for 2 h with either serum free medium, 1 mM N-
54
55
56
57
58
59
60

1
2
3 acetylcysteine (NAC) or 1 mM Vitamin C. Medium was removed and replaced with Hanks
4 Buffered Salt Solution (HBSS) containing 100 μ M DCDHF and incubated at 37°C for 50 min.
5
6 Following incubation the dye was replaced with either HBSS media alone (control), 500 μ M
7
8 H₂O₂ (positive control) or 1 μ M STS in the presence or absence of 1 mM NAC or 1 mM Vitamin
9
10 C for 1.5 h. The concentration of anti-oxidants used was based on viability assays (using the
11
12 MTT assay, data not shown) and information from previously published work (Spina *et al.*
13
14 1992). Changes in DCDHF fluorescence were monitored using a Leica CLSM inverted confocal
15
16 laser scanning microscope. Increase in cytosolic dichloro-fluorescein (DCF) fluorescence
17
18 reflected elevated intracellular ROS production. All images were taken using the same laser
19
20 power, gain and objective.
21
22
23
24
25
26
27
28
29

30 Immunohistochemistry

31
32 Human liver sections (4 μ m) fixed in 2 % (v/v) para-formaldehyde in PBS for 4 h, cryo-
33
34 protected in 15 % sucrose solution for 72 h, or SH-SY5Y cells fixed in 90 % (v/v) ice cold
35
36 methanol in TBS and incubated at -20°C for 20 min, were permeabilised with 0.5 % (v/v) Triton
37
38 X-100 in PBS for 5 min at room temperature then washed in PBS. Slides were blocked for 20
39
40 min with 20 % (v/v) normal swine serum in PBS and then incubated overnight in monoclonal
41
42 antibody, anti-MAO-A (6G11-E1) or anti-MAO-B (3F12-G10-2E3) (tissue culture supernatants),
43
44 or PBS as a negative control at room temperature. The slide was washed in PBS and then
45
46 incubated with secondary antibody; horseradish peroxidase conjugated anti-mouse
47
48 immunoglobulin G (dilution 1:100) in 5 % v/v normal swine serum in PBS for 30 min at room
49
50 temperature. The slide was washed in PBS and antibody binding revealed by incubation in DAB
51
52 substrate for 40 min and stopped with excessive washing in cold water.
53
54
55
56
57
58
59
60

Quantitative and conventional RT-PCR

Total RNA was isolated from SH-SY5Y cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and was reversely transcribed into the corresponding cDNA using oligo d(T)₁₈ and Superscript II reverse transcriptase (Invitrogen, Karlsruhe, Germany) according to the vendors instructions. Quantitative PCR was carried out with a Bio-Rad iCycler system, using the iQ SYBR Green Supermix kit from Bio-Rad (Bio-Rad, California, U.S.A). The following primers were used: MAO A, 5'-GCC CTG TGG TTC TTG TGG TAT GT-3', 5'-TGC TCC TCA CAC CAG TTC TTC TC-3' and GAPDH, 5'-CCA TCA CCA TCT TCC AGG AGC GA-3', 5'-GGA TGA CCT TGC CCA CAG CCT TG-3' and the following PCR protocol applied: 3 min initial denaturation and activation of the iTaq DNA polymerase at 95°C, followed by 45 cycles of denaturation (20 s at 95°C), annealing (30 s at 65°C) and elongation (30 s at 72°C). After that melting curve analysis was performed in order to confirm the homogeneity of the PCR product by continuous measuring and slowly decreasing the temperature from 95°C to 60°C. For exact quantification standard curves were generated for each target gene used as external standards. Specific amplicons of each target gene were cloned into the vector pCR2.1 (Invitrogen, Karlsruhe, Germany) following the vendors instruction, sequenced and serial dilutions ($1 \times 10^6 - 1 \times 10^2$ single stranded DNA molecules) were prepared and used as template applying the above quantitative PCR approach. GAPDH mRNA was used as internal standard to normalize MAO-A mRNA. Each sample was run in duplicate and the results represent the mean of three independent sets of experiments.

Conventional PCR was performed with a TECHNE TC-412 thermal cycler, using the Advantage 2 Polymerase Mix (Takara Bio Europe, France) according to the vendor's instructions. After 32

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PCR cycles PCR products were separated on a 2% agarose gel in 1×TAE buffer (40 mM Tris-HCl, pH 8.1; 0.2 mM EDTA; 20 mM acetic acid) in the presence of ethidium bromide (0.2 µg/ml). The gel was visualised with the GENE Genius Imaging System, using the GeneSnap software (version 5, SynGene, United Kingdom).

Statistical Analysis

All data shown are mean corrected values ±SEM and statistical analysis was performed using the Student's unpaired t-test to identify significant data, where confidence values (*p* values) of <0.05, <0.01, and <0.001 are marked by *, ** and *** respectively.

RESULTS

The MAO-A isoform is predominant in SH-SY5Y cells

Dopaminergic SH-SY5Y cells have previously been reported to contain both MAO isoforms (Song and Ehrich, 1998); whilst others (Yi *et al.* 2006) have suggested the presence of only MAO-A in these cells. This prompted us to initially characterise the expression of MAO isoforms in our cell model. MAO activity was measured *in vitro* in SH-SY5Y cell homogenates following titration with specific and irreversible inhibitors of MAO-A (clorgyline) and MAO-B (deprenyl) (Fig. 1A). Complete inhibition of MAO activity was achieved with 10⁻⁸ M clorgyline, whereas 10⁻⁵ M deprenyl was required to inhibit MAO (Fig. 1A), suggesting MAO-A prevalence in this cell line. Clorgyline has previously been shown to inhibit MAO-A activity in *in situ* experiments using SH-SY5Y cells at a concentration of 10⁻⁶ M (Yi *et al.* 2006). To support our activity assays, expression of the MAO isoforms was investigated at the protein and messenger

1
2
3 level. Analysis of MAO-A protein involved the use of a MAO-A specific monoclonal antibody,
4
5
6 previously characterised and shown to be useful for both immunohistochemistry (Church *et al.*
7
8 1994; Rodriguez *et al.* 2000) and quantitative immunoassays (Sivasubramaniam *et al.* 2002),
9
10 whilst MAO-B protein was detected using a MAO-B-specific antibody (Billett and Mayer,
11
12 1986). MAO-A but not MAO-B protein was detected in SH-SY5Y cells (Fig. 1B) using
13
14 immunohistochemical analysis with specific anti-MAO-A and MAO-B monoclonal antibodies.
15
16 In contrast, control human liver sections exhibited positive staining for MAO-A and -B (Fig.
17
18 1B). Semi-quantitative reverse transcription-polymerase chain reactions (RT-PCR) revealed an
19
20 intense signal for MAO-A indicating strong expression of the MAO-A messenger (Fig. 1C). In
21
22 contrast, no signal was observed for MAO-B messenger. Finally, using the more sensitive
23
24 approach of quantitative RT-PCR (qRT-PCR), average MAO-A mRNA expression of 2.58 ± 1.00
25
26 molecules/1000 molecules GAPDH was measured, whereas MAO-B mRNA levels were hardly
27
28 detectable (0.0006 ± 0.0005 molecules/1000 molecules GAPDH, data not shown).
29
30
31
32
33
34
35

36 **STS induces an increase in MAO-A catalytic activity and protein levels prior to activation** 37 38 **of caspase 3**

39
40 In order to establish a model of neuronal apoptosis, SH-SY5Y cells were induced to
41
42 undergo apoptotic cell death via the addition of staurosporine (STS). Initial titration studies
43
44 established that 1 μ M STS produced apoptotic cell morphologies (cellular blebbing etc.), but the
45
46 cells were still viable after 6 h (MTT reduction assay, data not shown). Treatment with 1 μ M
47
48 STS consistently resulted in caspase-3 activation (approximately 7 fold of control levels at 3-6 h,
49
50 Fig. 2). In addition, caspase-3 activation was preceded by a significant (2-3 fold) increase in
51
52 MAO catalytic activity, suggesting that increased MAO activity could play a role in early
53
54
55
56
57
58
59
60

1
2
3 apoptotic events. Increased MAO activity was associated with a significant but transient increase
4
5 in MAO-A protein (2-3 fold, Fig. 3A).
6
7
8
9

10 **MAO-A mRNA expression is not changed in STS-induced apoptosis**

11
12 Quantitative reverse transcription-polymerase chain reactions (qRT-PCR) were
13
14 performed to determine whether increases in MAO-A protein and activity were a result of
15
16 increased MAO-A mRNA expression. No significant changes in MAO-A mRNA steady state
17
18 levels were detected following 1 μ M STS treatment over a three-h apoptotic time course (Fig.
19
20
21
22 3B).
23
24
25
26

27 **The intrinsic but not the extrinsic pathway is active in STS-induced Apoptosis**

28
29 To investigate the upstream initiators of caspase-3, activation of caspase-8 and caspase-9
30
31 was monitored by Western blotting using specific antibodies directed against both the pro- and
32
33 active-forms of caspases-8 and -9. Caspase-9 was activated, one h following STS exposure and
34
35 remained active for the following 5 h (Data not shown; see Fig. 4 for 3 h time point). However,
36
37 no activation of caspase-8 was detected, despite the presence of caspase 8 protein and caspase-8
38
39 mRNA as detected by Western blot and qRT-PCR respectively (data not shown).
40
41
42
43
44
45

46 **Inhibition of MAO-A protects cells from STS-induced apoptosis**

47
48 The MAO inhibitors clorgyline and tranylcypramine both inhibit *in situ* MAO activity in
49
50 SH-SY5Y cells in the presence and absence of STS during a 4 h time period (Fig. 4A). Caspase-
51
52 3 activity was measured following inhibition of MAO-A in this apoptotic model to investigate
53
54 the relevance of MAO in the apoptotic cascade. Both clorgyline and tranylcypramine
55
56
57
58
59
60

1
2
3 significantly reduced caspase-3 activation by 50 % and 35 % respectively (Fig. 4B). Activation
4
5 of the upstream initiator Caspase-9 during STS-induced apoptosis was significantly reduced to
6
7 ~50 % by clorgyline, compared to STS treated cells alone (Fig. 4C).
8
9

10 Inhibition of MAO-A also improves the viability of STS treated cells. Cell viability,
11
12 measured using the MTT reduction assay, was reduced by 10% over a 3-h exposure to STS. The
13
14 MAO inhibitors clorgyline and tranylcypromine reduced this effect, which was significant after 1
15
16 h (supplementary data, Figure S1A). Morphological observations also demonstrated that
17
18 inhibition of MAO-A improved viability. Figure S1B shows that after 3-h exposure, STS
19
20 treatment results in a typical apoptotic phenotype, with cells being shrunk and rounded (compare
21
22 panels a and d). The addition of clorgyline and tranylcypromine at the same time as STS
23
24 significantly improved the condition of the cells, with axonal outgrowths being evident (compare
25
26 panels b and c with respectively panels e and f).
27
28
29
30
31
32
33

34 **Involvement of MAPK signalling pathways in MAO-enhanced apoptosis**

35
36 MAPK phosphorylation cascades are activated following oxidative stress (Finkel, 1998),
37
38 are involved in the activation of MAO-B expression (Wong *et al.* 2002) and in pro-apoptotic
39
40 MAO-A expression (DeZutter and Davis, 2001). To examine the potential involvement of
41
42 MAPK signalling in MAO-enhanced apoptosis, we investigated the levels of phosphorylated
43
44 (activated) protein kinases ERK, JNK and p38 during STS induced apoptosis. As shown in
45
46 Figure 5A, STS resulted in sustained increases in the levels of phosphorylated ERK, JNK and
47
48 p38 compared to controls, starting at approximately the same time as MAO activation (Figure 2).
49
50 Inhibition of MAO-A with clorgyline attenuated these effects, reducing the levels of
51
52
53
54
55
56
57
58
59
60

1
2
3 phosphorylated p38, JNK and ERK back to control levels. These data suggest that MAPK
4 signalling pathways are likely to be important in MAO-mediated apoptosis.
5
6
7
8
9

10 **Inhibition of MAO-A prevents Bcl-2 depletion during STS-Induced apoptosis**

11
12 The Bcl-2 family of proteins are critical in apoptotic signalling because of their anti- and
13 pro-apoptotic effects at the mitochondrial surface. As seen in Figure 5B, STS induced depletion
14 of Bcl-2 levels and clorgyline alone had no effect on Bcl-2 levels. When the cells were exposed
15 to clorgyline and STS together, Bcl-2 protein expression was maintained at the control level (Fig.
16 5B).
17
18
19
20
21
22
23
24
25
26

27 **Inhibition of MAO-A and addition of antioxidants has a similar effect on ROS formation** 28 **and caspase-3 activation**

29
30 MAO-A produces H₂O₂ as a by-product of its enzymatic action. We hypothesised that
31 MAO-A derived ROS might contribute to apoptotic signalling in our cell model. Hence
32 antioxidants should mimic the effect of MAO-A inhibition in apoptotic signalling. Exposure of
33 SH-SY5Y cells to 1 µM STS resulted in the production of high levels of ROS. This effect was
34 lessened by concomitant treatment with 1 µM clorgyline or the anti-oxidant N-acetyl cysteine
35 (NAC, 1 mM). However, 1 mM vitamin C was less effective (Fig. 6A). NAC but not vitamin C
36 significantly protected cells from caspase-3 activation (Fig. 6B). These data indicate that MAO-
37 generated oxidative stress is involved in apoptotic signalling.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

In SH-SY5Y cells staurosporine activates caspase-9 and -3 and thus initiates the intrinsic apoptotic pathway. In contrast, the extrinsic route, which depends on agonist binding to cell surface death receptors, remained unaffected, despite the cells containing caspase 8 protein and also caspase 8 mRNA (data not shown). These data are consistent with previously reported results obtained in a similar cellular model (Lopez and Ferrer, 2000). The activation of the mitochondrial apoptotic pathway in this model is of special interest considering the intracellular localisation of MAO in the outer mitochondrial membrane.

Our studies demonstrated that MAO-A activity was increased prior to caspase-3 activation and that inhibition of MAO activity significantly reduced caspase activation and loss in cell viability. To improve the reliability of our experimental data we used two independent MAO inhibitors with different modes of action. Clorgyline preferentially inhibits MAO-A, but is structurally related to the MAO-B inhibitor deprenyl and other propargyl deprenyl analogues such as *N*-propargyl-1(*R*)-aminoindan (rasagiline) and the compound CGP3466 (now in clinical trials for PD). The propargylamine-containing deprenyl analogues have been reported to possess neuroprotective and anti-apoptotic properties (Holt *et al.* 2004; Akao *et al.* 2002; Tatton *et al.* 1994). These neuroprotective properties, rather than being a result of MAO inhibition, are thought to be due, at least partly, to the inhibition of pro-apoptotic translational machinery (Kragten *et al.* 1998; Berry and Boulton, 2000), and induction of anti-apoptotic Bcl-2 family proteins (Kragten *et al.* 1998). Clorgyline has previously been shown to protect against apoptosis (DeZutter and Davis, 2001), serum withdrawal-induced loss in cell viability (Ou *et al.* 2006) and MPTP induced neurotoxicity (DeGirolamo *et al.* 2001). Whether or not the protective effects are

1
2
3 due solely to MAO inhibition has not been investigated. Indeed in our system clorgyline had no
4 effect on Bcl-2 levels, at least in control cells. To confirm that the effects of clorgyline were a
5 result of MAO inhibition, tranylcypromine was used as a second MAO inhibitor since it contains
6 no propargyl moiety, but interacts irreversibly with the flavin group. Tranylcypromine inhibits
7 both MAO-A and MAO-B but, because of the lack of MAO-B expression in our cell model, the
8 protection of the cells from apoptosis can be attributed to its inhibition of MAO-A. This confirms
9 that MAO-A is functional in neuronal cell apoptosis. Although a link between MAO and
10 mitochondrial damage is well established (Berman and Hastings, 1999; Cohen and Kesler, 1999)
11 and mitochondria are vital players in apoptotic signalling, a direct role for MAO-A in apoptosis
12 has only been claimed by De Zutter and Davis (2001) and, very recently, by Ou (Ou *et al.* 2006).
13 However, these authors did not attempt to link the apoptotic effects to ROS production by MAO-
14 A activity.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34 ROS formation was substantially increased following STS treatment and inhibition of MAO by
35 clorgyline and treatment with the antioxidant N-acetyl cysteine (NAC, a precursor of glutathione
36 and an anti-oxidant in its own right) reduced ROS to a similar extent. The fact that both
37 clorgyline and NAC also reduced caspase-3 activation indicates that ROS are the result of MAO
38 activity. The anti-oxidant vitamin C was also used but was less effective than NAC or clorgyline
39 in reducing both ROS production and caspase-3 activation. The reason for this is not clear but it
40 may be related to the fact that vitamin C, although a potent anti-oxidant, is considered to be toxic
41 in some circumstances, especially in the presence of metal ions and H₂O₂ (reviewed by
42 Halliwell, 1999).
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 MAO may be important in the early phase of apoptosis, before the execution of downstream
4 processes, since peak MAO activity and ROS production occur prior to peak caspase-3 activity.
5
6 Apoptosis is highly regulated, the mechanisms of which are still not fully understood, not only
7 because there is a wide range of cell death types ranging between classical apoptosis to classical
8 necrosis, but also because of variation depending on the nature of the inducer. However it is
9 thought that apoptosis is the predominant form of neuronal cell death in chronic
10 neurodegenerative diseases (Emerit *et al.* 2004). Thus the fact that MAO has an active role in
11 this process is of high significance.
12
13
14
15
16
17
18
19
20
21
22
23

24 We also demonstrate that MAO protein levels are increased, albeit transiently, and without a
25 concomitant increase in MAO-A mRNA levels. This implies that in our apoptotic model,
26 increases in MAO protein are due to post-transcriptional events. This could include a decrease in
27 MAO protein degradation or an increase in mRNA translation. However little is known about
28 these processes. In contrast, transcriptional activation of the MAO-A gene was seen following
29 withdrawal of nerve growth factor in rat PC12 cells (DeZutter and Davis, 2001, which has been
30 related to pro-apoptotic signalling) and in SH-SY5Y cells (Fitzgerald *et al.*, 2007). In addition,
31 Ou and co-workers (2006) recently found that MAO-A mRNA expression is also induced
32 following serum starvation, mediated by a reduction in the expression of the transcriptional
33 repressor R1. These different findings suggest that there are various regulatory mechanisms of
34 cell death that could regulate MAO-A expression at different levels of gene expression.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 Bcl-2 is an anti-apoptotic protein that plays a central role in mitochondrially mediated-apoptosis
54 and survival due to its strong influence on the balance of pro- and anti-apoptotic proteins that
55
56
57
58
59
60

1
2
3 also reside on the mitochondrial surface. Depletion of Bcl-2 is thought to be one of the first
4
5 initiators of the apoptotic cascade, since this shifts the balance of Bcl-2 family proteins in favour
6
7 of apoptosis, triggering the release of cytochrome *c* from the mitochondria (Hengartner, 2000).
8
9 STS exposure resulted in depletion of Bcl-2 levels in our model and was prevented by clorgyline,
10
11 suggesting that MAO is acting upstream of Bcl-2. This is contrary to the situation in serum
12
13 withdrawal, where MAO appears to act downstream of Bcl-2 (Ou *et al.* 2006). However, these
14
15 differences may reflect the different apoptotic inducers used and further work needs to be carried
16
17 out to clarify this.
18
19
20
21
22
23

24
25 The highly conserved mitogen-activated protein kinase (MAPK) cascades (Robinson and Cobb,
26
27 1997) are among the pathways often used to transduce mammalian stress signals. They have
28
29 been extensively described as crucial in regulating stress/survival responses and hence play an
30
31 important and universal role in mechanisms of cell death. Following STS-induced apoptosis the
32
33 extracellular regulated kinase (ERK), thought to be activated by mitotic stimuli was activated,
34
35 co-occurring with increases in MAO-A activity (Figures 2 and 5). Activation of p38 and c-jun N-
36
37 terminal kinase (JNK) generally activated by pro-inflammatory or stressful stimuli, also occurred
38
39 at the same time as ERK. MAO inhibition by clorgyline attenuated the activation of these
40
41 pathways to control levels. Thus MAPK signalling modules are involved in STS induced
42
43 apoptosis and ROS generated by MAO are involved in initiating these pathways (since MAO
44
45 inhibition reduced MAPK activation). Indeed H₂O₂ (a product of a MAO catalysed reaction) has
46
47 previously been shown to activate MAPK proteins (Guyton *et al.* 1996). Whether or not the
48
49 MAO gene is also a target of the MAPK pathways as described by DeZutter and Davis (2001)
50
51 and Wong (Wong *et al.* 2002) was not addressed in the present paper, but would seem unlikely
52
53
54
55
56
57
58
59
60

1
2
3 given that MAO mRNA levels were unchanged following STS treatment. However, in our model
4
5 it is clear that MAPK signalling is recruited to transmit pro-apoptotic stress signals following
6
7 STS exposure.
8
9

10
11
12 In conclusion, data in this report suggest a dynamic role for MAO-A in STS-induced neuronal
13
14 apoptosis, driven by the ability of MAO to generate oxidative stress in its prime position on the
15
16 mitochondrial surface. Our data support the supposition that MAO plays a key role in the
17
18 modulation of apoptotic signalling in response to biological stressors. These findings may have
19
20 wider implications for the therapeutic use of the dopamine precursor, levodopa, in PD and pre-
21
22 disposition to neurodegenerative diseases.
23
24
25
26
27
28

29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACKNOWLEDGEMENTS

This work was supported by grants from The British Council, Deutscher Akademischer Austauschdienst (DAAD) and The Leverhulme Trust.

REFERENCES

- Abou-Sleiman, P. M., Muqit, M. M. K. and Wood, N. W. (2006). Expanding insights of mitochondrial dysfunction in Parkinson's disease. *Nature Neuroscience* **7**, 207-219.
- Akao, Y., Maruyama, W., Yi, H., Shamoto-Nagai, M., Youdim, M., B. H, and Naoi, M. (2002). An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (Rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. *Neurosc. Lett.* **326**, 105-108

- 1
2
3
4 Bach, A. W. J., Lan, N. C., Johnson, D. L., Abell, C. W., Bembenek, M. E., Kwan, S., Seeburg,
5
6 P. H., and Shih, J. C. (1988). cDNA cloning of human liver monoamine oxidase A and B:
7
8 Molecular basis of differences in enzymic properties. *Proc. Natl. Acad. Sci. USA.* **85**,
9
10 4934-4938
11
- 12
13 Berman, S. B., and Hastings, T. G. (1999). Dopamine oxidation alters mitochondrial respiration
14
15 and induces permeability transition in brain mitochondria: Implications for Parkinson's
16
17 Disease. *J. Neurochem.* **73**, 1127-1137
18
- 19
20 Berry, M., D, and Boulton, A. A. (2000). Glyceraldehyde-3 Phosphate Dehydrogenase and
21
22 apoptosis. *J. Neurosc. Res.* **60**, 150-154
23
- 24
25 Billett, E. E. (2004). Monoamine Oxidase (MAO) in human peripheral tissues. *Neurotoxicology.*
26
27 **25**, 139-148
28
- 29
30 Billett, E.E. and Mayer, R.J. (1986). Monoclonal antibodies to monoamine oxidase B and another
31
32 mitochondrial protein from human liver. *Biochem. J.* **235**, 2157-2163
33
- 34
35 Cadenas, E., and Davies, K. J. A. (2000). Mitochondrial free radical generation, oxidative stress,
36
37 and aging. *Free Rad. Biol. Med.* **29** (3/4), 222-230
38
- 39
40 Church, R.J., Robinson, G. and Billett, E.E. (1994). The localisation of monoamine oxidase in
41
42 human placenta using a new specific monoclonal antibody to monoamine oxidase A. *Proc.*
43
44 *R. Microsc. Soc.* **29**, 243.
45
- 46
47 Cohen, G., and Kesler, N. (1999). Monoamine oxidase and mitochondrial respiration. *J.*
48
49 *Neurochem.* **73**, 2310-2315
50
- 51
52 De Girolamo, L. A., Hargreaves, A. J. and Billett, E. E. (2001). Protection from MPTP-induced
53
54 neurotoxicity in differentiating mouse N2a neuroblastoma cells. *J. Neurochem.* **76**, 650-
55
56 660
57
58
59
60

- 1
2
3 DeZutter, G. S., and Davis, R. J. (2001). Pro-apoptotic gene expression mediated by the p38
4
5 mitogen-activated protein kinase signal transduction pathway. *Proc. Natl. Acad. Sci. USA*.
6
7
8 **98**(11), 6168-6173
9
- 10 Emerit, J., Edeas, M., and Bricaire, F. (2004). Neurodegenerative diseases and oxidative stress.
11
12 *Pharmacotherapy*. **58**, 39-46
13
- 14 Finkel, T. (1998). Oxygen radicals and signaling *Curr. Opinion in Cell Biology*. **10**, 248-252
15
- 16 Fitzgerald, J. C., Ufer, C and E, E. Billett. 2007. A link between monoamine oxidase-A and
17
18 apoptosis in serum deprived human SH-SY5Y neuroblastoma cells. *J. Neural. Transm.*
19
20
21 **114**(6), 807-810.
22
- 23 Fowler, C. J., and Tipton, K. F. (1984). On the substrate specificities of the two forms of
24
25 monoamine oxidase *J. Pharm. Pharmacol.* **36**(2), 111-115
26
- 27 Guyton, K. Z., Liu, Y., Gorospe, M., Xu, Q., and Holbrook, N. J. (1996). Activation of Mitogen
28
29 activated Protein Kinase by H₂O₂. *J. Biol. Chem.* **271**(8), 4138-4142
30
31
- 32 Halliwell, B. 1999. Vitamin C: poison, prophylactic or panacea? *TIBS*. **24**, 255-259.
33
- 34 Hauptmann, N., Grimsby, J., Shih, J. C. and Cadenas, E. (1996). The metabolism of tyramine by
35
36 monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. *Arch. Biochem.*
37
38 *Biophys.* **335**, (295-304)
39
- 40 Hengartner, M. O. (2000). The biochemistry of apoptosis. *Nature*. **407**, 770-776
41
42
- 43 Holt, A., Berry, M., D, and Boulton, A. A. (2004). On the binding of monoamine oxidase
44
45 inhibitors to some sites distinct from the MAO active site, and effects thereby elicited.
46
47
48 *Neurotoxicol.* **25**, 251-266
49
- 50 Kragten, E., Lalande, I., Zimmermann, K., Roggo, S., Schindler, P., Muller, D., Van Oostrum, J.,
51
52
53 and Furst, P. (1998). Glyceraldehyde-3-phosphate Dehydrogenase, the putative target of
54
55
56
57
58
59
60

1
2
3 the anti-apoptotic compounds CGP 3466 and R-(-)-Deprenyl. *J. Biol. Chem.* **273**(10),
4 5821-5828
5
6

7
8 Kumar, M. J., Nicholls, D. G., and Anderson, J. K. (2003). Oxidative Alpha-Ketoglutarate
9 Dehydrogenase inhibition via subtle elevations in Monoamine Oxidase B levels results in
10 loss of spare respiratory capacity. *J. Biol. Chem.* **278**(47), 46432-46439
11
12

13
14 Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951). Protein measurement
15 with the Folin phenol reagent. *J. Biol. Chem.* **193**, 265-275
16
17

18
19 Lopez, E., and Ferrer, I. (2000). Staurosporine- and H-7-induced cell death in SH-SY5Y
20 neuroblastoma cells is associated with caspase-2 and caspase-3 activation, but not with
21 the activation of the FAS/FAS-L-caspase-8 signaling pathway. *Brain Res. Mol Brain Res.*
22 **85**(1-2), 61-67
23
24

25
26 Ou, X., Chen, K., and Shih, J. C. (2006). Monoamine oxidase A and repressor R1 are involved in
27 apoptotic signaling pathway. *Proc. Natl. Acad. Sci. USA.* **103**(29), 10923-10928
28
29

30
31 Riederer, P., Sofic, E., Rausch, W. D., Schmidt, B., Reynolds, G. P., Jellinger, K., and Youdim,
32 M. B. (1989). Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian
33 brains. *J. Neurochem.* **52**(2), 515-520
34
35

36
37 Robinson, M. J., and Cobb, M. H. (1997). Mitogen activated protein kinase signalling pathways.
38 *Curr. Opin. Cell. Biol.* **9**, 180-186
39
40

41
42 Rodriguez, M.J., Saura, J., Finch, C., Mahy, N. and Billett, E.E. (2000). Localization of monoamine
43 oxidase -A and -B in human pancreas, thyroid and adrenal glands. *J. Histochem. Cytochem.*,
44 **48** (1), 147-151.
45
46

47
48 Russell, S. M., and Mayer, R. J. (1983). Degradation of transplanted rat liver mitochondrial-
49 outer-membrane proteins in hepatoma cells. *Biochem. J.* **216**, 163-175
50
51
52

- 1
2
3 Schulz, J. B., Lindenau, J., Seyfried, J., and Dichgans. (2000). Glutathione, oxidative stress and
4 neurodegeneration. *Eur. J. of Biochem.* **267**, 4904-4911
5
6
7
8 Shih, J. C., Chen, K., and Ridd, M. J. (1999). Monoamine oxidase: From genes to behavior. *Ann.*
9
10 *Rev. Neuroscience.* **22**, 197-217
11
12
13 Sivasubramaniam, S.D., Finch, C.C, Billett, MA, Baker PH and Billett E.E. (2002). Monamine
14 oxidase expression and activity in human placentae from pre-eclamptic and normotensive
15 pregnancies. *Placenta* **23** (2-3), 163-171.
16
17
18
19
20 Song, X., and Ehrlich, M. (1998). Uptake and metabolism of MPTP and MPP⁺ in SH-SY5Y
21 human neuroblastoma cells. *In Vitro Mol. Toxicol.*(1), 3-12
22
23
24
25 Spina, M. B., Squinto, S. P., Miller, J., Lindsay, R. M. And Hyman, C. (1992). Brain-Derived
26 Neurotrophic Factor protects dopamine neurons against 6- Hydroxydopamine and N-
27 Methyl-4-Phenylpyridinium ion toxicity: involvement of the glutathione system. *J.*
28
29
30
31
32 *Neurochem.* **59**(1), 99-106.
33
34
35 Stokes, A. H., Hastings, T. G. and Vrana, K. E. (1999). Cytotoxic and genotoxic potential of
36 dopamine. *J. Neurosci. Res.* **55**, 659-665
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Tatton, W. G., Ju, W. Y. L., Holland, D. P., Tai, C., and Kwan, M. (1994). (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis *J. Neurochem.* **63**(4), 1572-157
- Tatton, W. G., and Olanow, W. (1999). Apoptosis in neurodegenerative diseases: the role of mitochondria. *Biochim. et Biophys. Acta* **1410**, 195-213
- Wong, W. K., Ou, X., Chen, K., and Shih, J. C. (2002). Activation of human monoamine oxidase B gene expression by a Protein Kinase C MAPK signal transduction pathway involves c-Jun and Egr-1. *J. Biol. Chem.* **277**(25), 22222-22230

1
2
3 Yi, H., Akao, Y., Maruyama, W., Chen, K., Shih, J. C., and Naoi, M. (2006). Type A monoamine
4
5 oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol,
6
7 leading to apoptosis in SH-SY5Y cells. *J. Neurochem.* **96**, 541-549
8
9

10 Yoon, S., Yun, C., and Chung, A. (2002). Dose effect of oxidative stress on signal transduction in
11
12 aging. *Mech. Ageing Dev.* **123**, 1597-1604
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Fitzgerald Figure 1




Fig. 1. MAO-A is predominant in SH-SY5Y human neuroblastoma cells (A) MAO Activity - activity was measured following addition of 0, 10^{-9} , 10^{-8} , 10^{-7} , 10^{-6} , 10^{-5} M clorgyline or deprenyl to SH-SY5Y cells *in vitro* via a radiometric method using 14 C-Tyramine as a substrate. Changes in MAO activity were determined in the presence or absence of the inhibitors and expressed % residual activity. (B) Immunohistochemistry - SH-SY5Y cells and human liver sections were stained with MAO-A (6G11-E1) and MAO-B (3F12/G10/2E3) specific antibodies and revealed using 3,3'-Diaminobenzidine. Control sections were incubated in the absence of MAO-specific antibodies but revealed under the same conditions. MAO specific immunoreactivity is represented by dark brown/red staining revealing the presence of MAO-A only in SH-SY5Y cells, but both MAO-A and MAO-B in human liver (control). The images shown are from a representative experiment. Scale bar represents 20 μ m. (C) RT-PCR - Agarose gel showing positive PCR controls (lanes 1,4 and 7), SH-SY5Y samples (lanes 2, 5 and 8) and negative PCR controls (lanes

1
2
3 **3, 6 and 9) for GAPDH, MAO-A and MAO-B gene expression.**
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Fitzgerald Figure 2




Fig. 2. Changes in MAO catalytic activity following STS treatment. Following addition of 1 μ M STS, MAO activity was measured in SH-SY5Y via a radiometric method, using 14 C-Tyramine as a substrate. MAO catalytic activity was expressed as pmoles/min/mg protein. Caspase-3 activation was measured to monitor the apoptotic time course, using Acetyl-Asp-Glu-Val-Asp-7-Amido methylcoumarin as substrate and expressed as Δ FU/min/ μ g protein. All data represent triplicate values from three independent experiments ($n=3$) and are expressed as mean \pm S.D. Treated samples were statistically compared to untreated controls at time zero using the Student's t-test where * $p < 0.05$, ** $p < 0.01$, * $p < 0.001$.**

Fitzgerald Figure 3




Fig. 3. MAO-A protein, but not MAO-A mRNA expression levels are induced by STS. (A) Left panel shows a dot blot of MAO-A protein levels following STS exposure. Equal protein homogenates were loaded on to a nitrocellulose membrane and probed with a MAO-A specific antibody. Mitochondrial outer membranes from human liver are the positive control and no primary antibody was the negative control. (A) **Right panel.** Quantification of blots in left panel. Blots were digitised and densitometry was performed to quantify relative MAO-A protein levels in all blots. These data represents values from four separate experiments ($n=4$) and expressed as mean arbitrary units (a.u.) \pm S. D. Statistical analysis of treated cells in comparison to untreated controls was carried out using the Student's t test, where $** p<0.01$, $*** p<0.001$. (B) MAO-A mRNA expression was measured by qRT-PCR following the addition of $1 \mu\text{M}$ STS for 3 h. Data represent duplicate values from three independent experiments ($n=3$). Values are expressed as means (% cf. untreated time zero control) \pm S.D. Statistical analysis of treated cells in comparison to untreated controls was performed using the Student's t-test, where no data was significant at $p<0.05$.

Fitzgerald Figure 4




Fig. 4. Inhibition of MAO-A reduces caspase-3 activity and caspase-9 activation in STS-induced apoptosis (A) MAO activity was measured in SH-SY5Y cells, 3 h following the addition of 1 μ M clorgyline (Clor), 1 μ M tranlylcypramine (TCP), 1 μ M STS, 1 μ M STS + 1 μ M clorgyline (S+C) or tranlylcypramine (S+T), and in untreated cells, using 14 C-Tyramine as a substrate. Changes in MAO activity were determined and expressed as experimental mean pmoles/min/mg protein \pm S.D. (B) Caspase-3 activity was measured in SH-SY5Y cells, 3 h following the addition of 1 μ M clor, 1 μ M TCP, 1 μ M STS, S+C, S+T and in untreated cells, using Acetyl-Asp-Glu-Val-Asp-7-Amido-methylcoumarin as a substrate. Caspase-3 activity was expressed as mean Δ FU/min/ μ g protein \pm S.D, where $n=3$. MAO/Caspase activities from clorgyline treated cells were compared to activities from cells exposed to STS alone using the Student's t-test, where ** $p=0.01$,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

***** $p=0.001$. (C) Western blot - activation of caspase-9 (pro-form/active form) was assessed in extracts of SH-SY5Y cells exposed to 1 μ M STS in the presence or absence of 1 μ M clorgyline following 3 h exposure. Equal protein aliquots (20 μ g) were separated on a 12 % (v/v) acrylamide SDS-PAGE gel prior to transfer to nitrocellulose filters. Blots were probed with anti-caspase-9 antibody (2 μ g/ml). Western blot shown is a representative blot of three independent experiments.**

For Peer Review

Fitzgerald Figure 5




Fig. 5. STS induces changes in MAPK signalling and Bcl-2 levels, which are attenuated by clorgyline. Equal protein aliquots (80 μ g for MAPK proteins and 20 μ g for Bcl-2) of cells extracts from SH-SY5Y cells exposed to 1 μ M clorgyline, 1 μ M STS or 1 μ M STS + 1 μ M clorgyline for a 3 h period were separated on a 12 % (v/v) acrylamide SDS-PAGE gel prior to transfer to nitrocellulose membranes. Blots were probed with antibodies directed to pERK (1:1000 dilution), pJNK (1:500 dilution) and pP38 (1:1000) (A) or by anti-bcl-2 antibody (1:750) (B). Equal loading was checked by probing for total ERK (1:1000 dilution), total JNK (1:750 dilution) and total p38 (1:1000 dilution). Blots shown are representative of three separate experiments.

Fitzgerald Figure 6




Fig. 6. Effect of clorgyline and antioxidants on ROS production in STS exposed SH-SY5Y cells. (A) Cells exposed to STS were treated with 1 μ M Clorgyline, 1 mM NAC or 1 mM Vitamin C for 4 h. DCDHF fluorescence was monitored over a 4 h period and visualised using a CLSM Leica microscope. Photomicrographs are shown at 1.5 h post-treatment and are representative of 3 independent experiments. Scale bar represents 20 μ m. (B) The effect of antioxidants NAC and vitamin C on caspase-3 activity were measured in SH-SY5Y cells following treatment (see above) for 2 h and measured using Acetyl-Asp-Glu-Val-Asp-7-Amidomethylcoumarin as a substrate. Caspase 3 activity was expressed as mean Δ FU/min/ μ g protein \pm S.D, where $n=3$. Statistical analysis of antioxidant treatment in the presence of STS was compared to STS treatment alone using the Student's t-test where ** $p<0.01$.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review